HEC Changjiang Pharma Out-licenses US Rights for Insulin Drug to Lannett

YiChang HEC Changjiang Pharma has out-licensed US rights for a generic insulin product to Lannett Company, a Philadelphia generic drugmaker. The insulin product is one of a five-drug package that Lannett has obtained. The other four were not disclosed, but according to YiChang HEC's website, it has five generic insulin products in development. Lannett will complete the US approval process for the insulin product. Financial details of the agreement were not disclosed. More details.... Stock Symbols: (HK: 1558) (NYSE: LCI) Share this with colleagues: // //